Wyeth Australia Pty Ltd

13 PBAC submissions on file, active 2005–2010. 46% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Etanercept
  Rheumatology · Recommended with restriction · 2025other sponsor
• Methylnaltrexone bromide
  Pain · Recommended with restriction · 2009—
• Pneumococcal polysaccharide conjugate vaccine, 13-valent
  Vaccines · Noted · 2018—
• Desvenlafaxine succinate
  Mental health · Recommended with restriction · 2008—
• Temsirolimus
  Oncology · Not recommended · 2008—

Therapy area mix

Activity by year

2005 (2) · 2006 (1) · 2007 (1) · 2008 (4) · 2009 (3) · 2010 (2)

Rejection patterns

Across 7 Not recommended decisions on file.

• 1×uncertain and unacceptable cost-effectiveness
• 1×considerable model uncertainty
• 1×biased assumptions regarding subsequent treatment cycles
• 1×unclear relationship between PASI and BSA scores
• 1×reliance on limited follow-up data for treatment-free period duration